Celldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Acquired by Values First Advisors Inc.

Values First Advisors Inc. boosted its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 13.4% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 24,172 shares of the biopharmaceutical company’s stock after purchasing an additional 2,853 shares during the period. Values First Advisors Inc.’s holdings in Celldex Therapeutics were worth $822,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in Celldex Therapeutics by 16.3% in the fourth quarter. Vanguard Group Inc. now owns 3,046,331 shares of the biopharmaceutical company’s stock valued at $120,817,000 after purchasing an additional 427,827 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in Celldex Therapeutics by 631.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,087,208 shares of the biopharmaceutical company’s stock worth $129,571,000 after buying an additional 2,664,915 shares during the last quarter. Swiss National Bank lifted its holdings in Celldex Therapeutics by 17.8% during the 1st quarter. Swiss National Bank now owns 114,300 shares of the biopharmaceutical company’s stock worth $4,797,000 after buying an additional 17,300 shares during the last quarter. Jennison Associates LLC lifted its holdings in Celldex Therapeutics by 3,327.0% during the 1st quarter. Jennison Associates LLC now owns 688,080 shares of the biopharmaceutical company’s stock worth $28,879,000 after buying an additional 668,002 shares during the last quarter. Finally, Bellevue Group AG lifted its holdings in Celldex Therapeutics by 15.7% during the 1st quarter. Bellevue Group AG now owns 2,796,615 shares of the biopharmaceutical company’s stock worth $117,374,000 after buying an additional 380,319 shares during the last quarter.

Analysts Set New Price Targets

Several analysts recently issued reports on CLDX shares. Citigroup started coverage on Celldex Therapeutics in a report on Monday, October 7th. They issued a “buy” rating and a $70.00 price target on the stock. The Goldman Sachs Group started coverage on Celldex Therapeutics in a research report on Monday, September 30th. They issued a “neutral” rating and a $45.00 target price on the stock. Wells Fargo & Company upgraded Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Thursday, September 26th. Wolfe Research cut Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a research report on Friday, September 27th. Finally, HC Wainwright restated a “buy” rating and issued a $80.00 target price on shares of Celldex Therapeutics in a research report on Thursday, September 26th. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $62.25.

Celldex Therapeutics Stock Down 1.9 %

Shares of Celldex Therapeutics stock opened at $28.13 on Friday. The stock has a market cap of $1.86 billion, a PE ratio of -10.27 and a beta of 1.55. The business has a fifty day simple moving average of $35.97 and a 200-day simple moving average of $36.80. Celldex Therapeutics, Inc. has a 12 month low of $22.11 and a 12 month high of $53.18.

Celldex Therapeutics (NASDAQ:CLDX) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.54) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.05. The business had revenue of $2.50 million during the quarter, compared to analysts’ expectations of $1.13 million. Celldex Therapeutics had a negative return on equity of 23.66% and a negative net margin of 1,809.18%. Analysts expect that Celldex Therapeutics, Inc. will post -2.5 EPS for the current fiscal year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.